Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance
Isocitrate dehydrogenase wild-type glioblastoma, a Grade 4 malignant brain neoplasm, remains resistant to multimodal treatment, with a median survival of 16 months from diagnosis with no geographical bias. Despite increasing appreciation of intra-tumour genotypic variation and stem cell plasticity,...
Saved in:
| Main Authors: | Pulkit Malhotra, Ruman Rahman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Onco |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-7523/4/4/24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glioblastoma Multiformе Tumour Stem Cells as Potential Therapeutic Targets
by: O. A. Beylerli, et al.
Published: (2019-11-01) -
Understanding the autophagic functions in cancer stem cell maintenance and therapy resistance
by: Niharika, et al.
Published: (2024-01-01) -
Recapitulating Glioma Stem Cell Niches Using 3D Spheroid Models for Glioblastoma Research
by: Hyunji Jo, et al.
Published: (2024-11-01) -
Causes of drug resistance and glioblastoma relapses
by: A. A. Mitrofanov, et al.
Published: (2021-04-01) -
Why Do Glioblastoma Treatments Fail?
by: Alen Rončević, et al.
Published: (2025-02-01)